

GlaxoSmithKline Pharmaceuticals

BSE SENSEX	S&P CNX	CMP: INR2,088	TP: INR2,272	Buy								
18,429	5,607											
Bloomberg Equity Shares (m)	GLXO IN 84.7	Year End	Net Sales (INR m)	PAT (INR m)	EPS (INR)	EPS Gr. (%)	P/E (X)	P/BV (X)	ROE (%)	ROCE (%)	EV/Sales	EV/EBITDA
52-Week Range (INR)	2,475/1,830	12/09A	18,708	5,049	59.6	12.6	-	-	28.7	43.0	-	-
1,6,12 Rel. Perf. (%)	-4/-11/-5	12/10A	21,116	5,814	68.6	15.2	-	-	30.1	44.8	-	-
M.Cap. (INR b)	176.9	12/11A	23,380	6,314	74.5	8.6	28.0	9.2	32.9	47.9	6.6	20.9
M.Cap. (USD b)	3.6	12/12E	26,742	7,402	87.4	17.2	23.9	8.5	35.7	52.9	5.8	17.0

- GlaxoSmithKline Pharmaceuticals (GLXO) posted net sales of INR5.66b (v/s our estimate of INR5.43b) for 4QCY12, up 15.4% YoY. EBITDA grew 15.8% YoY to INR1.71b (v/s our estimate of INR1.62b) while adjusted PAT increased 20.5% YoY to INR1.47b (v/s our estimate of INR1.3b).
- While overall revenue growth was 15.4% YoY, revenue from the core pharmaceuticals business grew by an impressive 18.2% YoY. Topline growth was led by revival in the Mass Market business and Anti-infectives segments. Vaccines and Specialty segments including Oncology, Dermatology, Cardiovascular and Metabolics reported robust double-digit growth, driven by new product launches.
- EBITDA grew 15.8% YoY to INR1.71b; EBITDA margin remained flat YoY at 30.1% (v/s our estimate of 29.8%). EBITDA was higher than estimated, primarily led by better than estimated topline growth.
- Adjusted PAT increased by 20.5% YoY to INR1.47b (v/s our estimate of INR1.3b), led by higher than estimated other income and lower effective tax rate. GLXO has declared INR45/share as dividend.

We believe GLXO is one of the best plays on the IPR regime in India, with aggressive plans to launch new products in the high-growth lifestyle segments. These launches should bring in long-term benefits. While we expect double-digit topline growth to sustain over the next few years, the growth trajectory should improve further post CY13, as new launches start contributing meaningfully. This growth is likely to be funded through miniscule capex and negative net working capital. GLXO deserves premium valuations due to strong parentage (giving access to large product pipeline), brand-building ability and likely positioning in the post-patent era. It is one of the very few companies, with the ability to achieve reasonable growth without any major capital requirement, leading to high RoCE of over 45%. We expect GLXO to record an EPS of INR87.4 (up 17.2%) in CY12. The stock currently trades at 23.9x CY12E EPS. Maintain **Buy**, with a target price of INR2,272 (26x CY12E EPS).

Quarterly Performance	(INR Million)									
	Y/E December	CY10				CY11				CY10
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
Net Sales	5,411	4,979	5,820	4,906	6,029	5,615	6,076	5,660	21,116	23,380
YoY Change (%)	18.4	8.9	13.7	10.4	11.4	12.8	4.4	15.4	12.9	10.7
Total Expenditure	3,410	3,163	3,733	3,433	3,920	3,746	4,316	3,954	13,739	15,935
EBITDA	2,001	1,817	2,087	1,473	2,109	1,870	1,760	1,706	7,378	7,445
Margins (%)	37.0	36.5	35.9	30.0	35.0	33.3	29.0	30.1	34.9	31.8
Depreciation	38	41	41	57	44	49	49	62	176	204
Interest	0	0	0	6	0	0	0	0	6	0
Other Income	438	298	328	413	580	421	441	532	1,477	1,975
PBT before EO Expense	2,402	2,074	2,374	1,823	2,645	2,242	2,152	2,177	8,673	9,216
Tax	790	678	792	600	782	725	692	703	2,859	2,902
Rate (%)	32.9	32.7	33.3	32.9	29.6	32.3	32.2	32.3	33.0	31.5
Adjusted PAT	1,612	1,396	1,583	1,223	1,863	1,517	1,460	1,474	5,814	6,314
YoY Change (%)	3.7	-19.6	-3.7	-7.4	15.6	8.6	-7.7	20.5	15.2	8.6
Margins (%)	29.8	28.0	27.2	24.9	30.9	27.0	24.0	26.0	27.5	27.0
Extra-Ord Expense	0	106	4	66	1,859	41	1	106	177	2,008
Reported PAT	1,612	1,290	1,578	1,157	5	1,475	1,459	1,367	5,637	4,306

E: MOSL Estimates

Nimish Desai (NimishDesai@MotilalOswal.com); Tel: +91 22 39825406


Amit Shah (Amit.Shah@MotilalOswal.com); Tel: + 91 22 3982 5423

Topline growth driven by revival in Mass Market and Anti-infectives segment

Net sales grew by 15.4% YoY to INR5.66b (v/s est of INR5.43b), EBITDA grew by 15.8% YoY to INR1.71b (v/s est of INR1.62b) while Adj PAT increased by 20.5% YoY to INR1.47b (v/s est INR1.3b).

While the overall revenue growth was at 15.4% YoY, revenue from core pharmaceutical business grew by impressive 18.2% YoY. Topline growth was led by revival in the Mass Market business and Anti-infectives segments. Vaccines and Specialty segment including Oncology, Dermatology, Cardiovascular and Metabolics reported robust double digit growth on the back of new product launches.

Revenue trend




Source: Company/MOSL

EBITDA increased by 15.8%, above estimates

EBITDA increased by 15.8% YoY to INR1.71b while EBITDA margin remained flat YoY at 30.1% (v/s est 29.8%). EBITDA was above estimates primarily led by better than estimated topline growth. Adj PAT increased by 20.5% YoY to INR1.47b (v/s est INR1.3b) led by higher than estimated other income and lower effective tax rate. The company has declared INR45/share as dividend.

EBITDA and margin trend



Source: Company/MOSL

Topline to grow in double digits; EBITDA margins to sustain at 33-35%

We expect GSK to sustain double-digit topline growth over the next two years led by focus on Priority Products, expanding therapeutic and geographic coverage, and

incremental contribution from new launches. We believe the company will be able to sustain EBITDA margin at ~35% despite the gradual increase in field force strength (200-300 per year). Planned investments in field force expansion for the year continued during the quarter. GSK's strong brand-equity with doctors enables it to sustain premium pricing for many of its brands resulting in high profitability. The main products launched in the last few quarters include Synflorix (vaccine against invasive pneumococcal disease), Mycamine (injectable anti-fungal, in-licensed from Astellas), Parit-D (in the GI segment – in-licensed from Esai), Modvate 3 & Modvate AF creams (both in the dermatology segments), branded generics for Atorvastatin and Rosuvastatin (both in the CVS segment), Revolcade and Votirent from GSK's pipeline in Oncology and Haematology, one in dermatology and one in branded generic segment.

Aggressive new launches

GSK is strongly committed to Indian operations, which is evident from the fact that many new products have been launched in CY08-10 period. This includes four vaccines including the latest Cervarix (cervical cancer vaccine for women) and Tykerb (anti-cancer). We believe that Cervarix, Rotarix (Rotavirus vaccine) and Eltrombopag (platelet aggregator) hold good long-term potential. It has attained the leadership position in the cervical cancer vaccine market despite launching Cervarix post Merck's launch of Gardasil. GSK has recently dropped prices of this vaccine (not quantified). In line with its strategy, GSK is gradually ramping up its presence in the high-growth lifestyle segments through a combination of launching product's from the parent's pipeline, in-licensing from other MNCs and launch of branded generics. Despite having a negligible contribution from the life-style segments, GSK currently enjoys one of the highest profitability in the industry (EBITDA margins of 35%).

Draft New Pharma Pricing Policy, if implemented in its current form, likely to impact earnings

The government has released the draft of the National Pharmaceuticals Pricing Policy, 2011 (NPPP). The proposed policy significantly increased the span of price control. All the 348 drugs, which are currently a part of the National List of Essential Medicines (NLEM) will be subjected to price control. Currently, only 74 drugs are under price control. Price control will be implemented on formulations of these drugs as compared to the current practice of controlling bulk drug price. Further, price control will also apply to combination drugs and to all the dosage strengths of the drugs.

If the policy is implemented in its current form, as per AIOCD analysis, GLXO's sales will impacted by INR1.51b (6% of revenue). This translates into 13.5% impact on earnings.

Upgrading earnings estimates by 3%

Based on 4QCY11 result and guidance given by the management, we have increased revenue estimates for CY12 by 1%. Consequently, we have increased earnings estimates for CY12 by 2.8%. Our estimates do not take into account the impact of NPPP.

Valuation and view

We believe GSK is one of the best plays on IPR regime in India with aggressive plans to launch new products in the high-growth life-style segments. These launches are expected to bring in long-term benefits. We believe GSK is likely to sustain double-digit topline growth over the next few years. We believe that this growth trajectory will improve further post CY13, as new launches start contributing meaningfully to topline. Given the high profitability of operations, we expect this growth to lead to sustainable double-digit earnings growth and RoE of ~30%. This growth is likely to be funded through miniscule capex and negative net working capital.

GSK deserves premium valuations due to strong parentage (giving access to large product pipeline), brand-building ability and likely positioning in post patent era. It is one of the very few companies with ability to drive reasonable growth without any major capital requirement leading to high RoCE of over 45%. Based on our revised estimates, we expect GSK to record CY12E EPS of INR87.4 (up 17.2%). The stock is currently valued at 23.9x CY12E. Maintain **Buy** with a target price of INR2,272 (26x CY12E).

GlaxoSmithKline Pharmaceuticals: an investment profile

Company description

GSK Pharma (50% subsidiary of GSK Plc) is the 4th largest formulations company and second largest pharma MNC in India, with a strong presence in segments like dermatology, respiratory and vaccines. Its parent has one of the richest product and R&D pipelines among Pharma companies worldwide.

Key investment arguments

- Excellent branded portfolio with strong presence in dermatology, respiratory and vaccines; increased focus on high margin-high growth “power brands” has improved product mix.
- Parent’s strong pipeline holds good upside potential post IPR implementation, with no conflict issues involved with any other subsidiary.
- GSK is strongly committed to its Indian operations, which is evident from the fact that 9 patented (or low-competition) products have launched in the CY08-10 period.

Key investment risks

- Biggest risk to GSK Pharma could be the implementation of the new pharmaceutical policy in the current form. The new policy proposes to significantly increase the span of control by bringing in additional 354 drugs under price control. This could severely impact the profitability of GSK Pharma’s business.

- Possible pre-grant and post-grant patent challenges by domestic generic companies could hamper the plans and prospects of launch of patented product by GSK Pharma in India.

Recent developments

- Launch of Votrient, indicated for the treatment of advanced renal cell carcinoma and Revolade for the treatment of reduced platelet count.

Valuation and view

- We believe GSK is one of the best plays on IPR regime in India. Parent is fully committed to the listed entity, which is evident from the fact that it is proposing to launch most of the patented products through the listed entity
- The stock is currently valued at 23.9x CY12E earnings. We maintain **Buy**.

Sector view

- The domestic market is expected to witness 12-13% growth, with gradual increase in the low penetration levels – companies with strong brands and marketing muscle to benefit. IPR regime unlikely to lead to any major change in the near term; MNCs and large Indian players to gain over the longer term.
- Among MNCs, we are bullish on companies whose domestic portfolio is well aligned with its parent and where risk of conflict with 100% subsidiaries is limited.

Comparative valuations

		GSK Pharma	Aventis
P/E (x)	CY11A	28.0	28.4
	CY12E	23.9	26.1
P/BV (x)	CY11A	9.2	4.7
	CY12E	8.5	4.2
EV/Sales (x)	CY11A	6.6	4.1
	CY12E	5.8	3.2
EV/EBITDA (x)	CY11A	20.9	29.9
	CY12E	17.0	21.7

Shareholding pattern (%)

	Dec-11	Sep-11	Dec-10
Promoter	50.7	50.7	50.7
Domestic Inst	15.6	15.5	16.2
Foreign	17.3	17.4	16.3
Others	16.4	16.5	16.9


EPS: MOSL forecast v/s consensus (INR)

	MOSL Forecast	Consensus Forecast	Variation (%)
CY11	74.5	71.0	4.9
CY12	87.4	84.4	3.6

Target Price and Recommendation

Current Price (INR)	Target Price (INR)	Upside (%)	Reco.
2,088	2,272	8.8	Buy

Stock performance (1 year)



N O T E S

Disclosures

This report is for personal information of the authorized recipient and does not constitute to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOST) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form.

Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOST or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOST or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOST or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

The information contained herein is based on publicly available data or other sources believed to be reliable. While we would endeavour to update the information herein on reasonable basis, MOST and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOST and/or its affiliates from doing so. MOST or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOST or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents.

MOST and/or its affiliates and/or employees may have interests/positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOST has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

Disclosure of Interest Statement

GlaxoSmithKline Pharmaceuticals

1. Analyst ownership of the stock	No
2. Group/Directors ownership of the stock	Yes
3. Broking relationship with company covered	No
4. Investment Banking relationship with company covered	No

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOST research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOST & its group companies to registration or licensing requirements within such jurisdictions.

For U.K.

This report is intended for distribution only to persons having professional experience in matters relating to investments as described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (referred to as "investment professionals"). This document must not be acted on or relied on by persons who are not investment professionals. Any investment or investment activity to which this document relates is only available to investment professionals and will be engaged in only with such persons.

For U.S.

MOST is not a registered broker-dealer in the United States (U.S.) and, therefore, is not subject to U.S. rules. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., Motilal Oswal has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, Marco Polo and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.



Motilal Oswal Securities Ltd

3rd Floor, Hoechst House, Nariman Point, Mumbai 400 021

Phone: (91-22) 39825500 Fax: (91-22) 22885038. E-mail: reports@motilaloswal.com